In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArQule Inc.

www.arqule.com

Latest From ArQule Inc.

Finance Watch: Gene Therapy, Targeted Oncology Driving IPOs Despite Biopharma Stock Shakiness

Public Company Edition: Jefferies report notes robust IPO market, but SVB Leerink predicts a financing slowdown. Also, Mirati raises cash for KRAS programs after Amgen's ASCO data and a strategic shift results in job cuts at ImmunoGen.

Financing Deals

Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track

Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.

Clinical Trials Cancer

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Financing Business Strategies

Start-up QED Touts Singular Focus On FGFR Inhibitor Infigratinib

Emerging Company Profile: With backing from BridgeBio, San Francisco start-up QED sees potential for drug licensed from Novartis in a number of tumor types, following the recent presentation of promising results in Phase II for bile duct cancer and Phase I for advanced urothelial cancer.

StartUps and SMEs Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Molecular Diversity
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ArQule Inc.
  • Senior Management
  • Paolo Pucci, CEO
    Marc Schegerin, PhD, CFO
    Peter S Lawrence, Pres. & COO
    Brian Schwartz, MD, CMO
  • Contact Info
  • ArQule Inc.
    Phone: (781) 994-0300
    One Wall St.
    Burlington, MA 01803
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register